These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024 [TBL] [Abstract][Full Text] [Related]
7. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2. Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Tom WL; Van Syoc M; Chanda S; Zane LT Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394 [TBL] [Abstract][Full Text] [Related]
9. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Hoy SM Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116 [TBL] [Abstract][Full Text] [Related]
11. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509 [TBL] [Abstract][Full Text] [Related]
12. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740 [TBL] [Abstract][Full Text] [Related]